Ever since the coronavirus disease 2019 (COVID-19) pandemic stuck, the challenges posed to the scientific community by its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been myriad, and still continue to emerge. Even though a host of repurposed and new therapeutic agents as well as vaccines have been, and are being assessed at a breakneck speed, this contagion continues to create havoc, returning back in waves, with appearance of newer viral variants which are associated with numerous challenges, which include greater transmissibility, increased virulence, immune escape, etc. We discuss the current status of various therapeutic agents which are being used, or in the various stages of preclinical / clinical trials for managing COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- clinical trial
- current status
- escherichia coli
- pseudomonas aeruginosa
- staphylococcus aureus
- mental health
- healthcare
- copy number
- antimicrobial resistance
- small molecule
- randomized controlled trial
- stem cells
- gene expression
- cystic fibrosis
- mesenchymal stem cells
- open label
- phase ii
- study protocol
- double blind